The demethylating agent 5-Aza reduces the growth, invasiveness, and clonogenicity of uveal and cutaneous melanoma

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 10, 2014, Pages 6178-6186

  Rajaii, Fatemeh ^a   Asnaghi, Laura ^a   Enke, Raymond ^b   Merbs, Shannath L ^a   Handa, James T ^a   Eberhart, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JAMES MADISON UNIVERSITY   (United States)

Author keywords

Demethylation; Epigenetics; Melanoma; Metastasis; Uveal melanoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GENOMIC DNA; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DNA; DNA METHYLTRANSFERASE;

ARTICLE; CANCER CELL CULTURE; CANCER CELL LINE; CANCER GROWTH; CELL GROWTH ASSAY; CELL INVASION ASSAY; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DNA METHYLATION; EPIGENETICS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; RADIATION EXPOSURE; TUMOR INVASION; TUMOR XENOGRAFT; UVEA MELANOMA; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CFU COUNTING; DRUG EFFECTS; MELANOMA; METABOLISM; MOUSE; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TUMOR CELL LINE; UVEAL NEOPLASMS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DNA MODIFICATION METHYLASES; DNA, NEOPLASM; HUMANS; MELANOMA; MICE; NEOPLASMS, EXPERIMENTAL; UVEAL NEOPLASMS;

EID: 84908101925     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-13933     Document Type: Article

References (41)

1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118: 1881-1885
2. Sarkar S, Goldgar S, Byler S, Rosenthal S, Heerboth S. Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics. 2013;5:87-94
3. Vecchio L, Seke Etet PF, Kipanyula MJ, Krampera M, Nwabo Kamdje AH. Importance of epigenetic changes in cancer etiology, pathogenesis, clinical profiling, and treatment: what can be learned from hematologic malignancies? Biochim Biophys Acta. 2013;1836:90-104
4. Zagni C, Chiacchio U, Rescifina A. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment. Curr Med Chem. 2013;20:167–185
5. Warnecke PM, Bestor TH. Cytosine methylation and human cancer. Curr Opin Oncol. 2000;12:68-73
6. van der Velden PA, Metzelaar-Blok JA, Bergman W, et al. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res. 2001; 61:5303-5306
7. Fahy J, Jeltsch A, Arimondo PB. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin Ther Pat. 2012;22:1427-1442
8. De Waard-Siebinga I, Blom DJ, Griffioen M, et al. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer. 1995;62:155-161
9. Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci. 1989;30:829-834
10. Luyten GP, Naus NC, Mooy CM, et al. Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int J Cancer. 1996;66:380-387
11. Ma D, Niederkorn JY. Transforming growth factor-beta downregulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology. 1995;86:263-269
12. Verbik DJ, Murray TG, Tran JM, Ksander BR. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer. 1997;73:470-478
13. Griewank KG, Yu X, Khalili J, et al. Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res. 2012;25:182-187
14. Folberg R, Kadkol SS, Frenkel S, et al. Authenticating cell lines in ophthalmic research laboratories. Invest Ophthalmol Vis Sci. 2008;49:4697-4701
15. Asnaghi L, Ebrahimi KB, Schreck KC, et al. Notch signaling promotes growth and invasion in uveal melanoma. Clin Cancer Res. 2012;18:654-665
16. Harning R, Szalay J. Ocular metastasis of in vivo and in vitro derived syngeneic murine melanoma. Invest Ophthalmol Vis Sci. 1987;28:1599-1604
17. Grossniklaus HE, Wilson MW, Barron BC, Lynn MJ. Anterior vs posterior intraocular melanoma. Metastatic differences in a murine model. Arch Ophthalmol. 1996;114:1116-1120
18. Grossniklaus HE, Barron BC, Wilson MW. Murine model of anterior and posterior ocular melanoma. Curr Eye Res. 1995; 14:399-404
19. Yang H, Akor C, Dithmar S, Grossniklaus HE. Low dose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model. Mol Vis. 2004;10:987-995
20. Yang H, Grossniklaus HE. Combined immunologic and antiangiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res. 2006;31:557-562
21. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis. 1997;15:509-518
22. Kili c E, Brüggenwirth HT, Verbiest M M, et al. The RAS-BRAF inase pathway is not involved in uveal melanoma. Melanoma Res. 2004;14:203-205
23. Maat W, Kilic E, Luyten GP, et al. Pyrophosphorolysis detects BRAF mutations in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:23-27
24. Pereira PR, Odashiro AN, Lim LA, et al. Current and emerging treatment options for uveal melanoma. Clin Ophthalmol. 2013;7:1669-1682
25. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol. 2010;37:127-138
26. Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J. 2012;18:148-152
27. Klisovic DD, Katz SE, Effron D, et al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci. 2003;44:2390-2398
28. Klisovic DD, Klisovic MI, Effron D, Liu S, Marcucci G, Katz SE. Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma. Melanoma Res. 2005;15:147-153
29. Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18:408-416
30. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev. 2008;34:247-258
31. van Groeningen CJ, Leyva A, O’Brien AM, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-aza-20-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986;46:4831-4836
32. Thibault A, Figg WD, Bergan RC, et al. A phase II study of 5-aza- 20deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori. 1998;84:87-89
33. Keating GM. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. Drugs. 2012;72:1111-1136
34. Janssen CS, Sibbett R, Henriquez FL, McKay IC, Kemp EG, Roberts F. The T1799A point mutation is present in posterior uveal melanoma. Br J Cancer. 2008;99:1673-1677
35. Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One. 2014;9: e83957
36. van der Velden PA, Zuidervaart W, Hurks MH, et al. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int J Cancer. 2003;106:472-479
37. Gollob JA, Sciambi CJ. Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells. Clin Cancer Res. 2007;13:5219-5225
38. Radosevich M, Jager M, Ono SJ. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator. Exp Mol Pathol. 2007;82:68-76
39. Kelderman S, van der Kooij MK, van den Eertwegh AJ, et al. Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol. 2013;52:1786-1788
40. Luke JJ, Callahan MK, Postow MA, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013;119:3687-3695
41. Maio M, Danielli R, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013;24:2911-2915